The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Siegel, R., Naishadham, D., & Jemal, A. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20138 · Cited by 10,679
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · cited 2×
“Three regimens are approved in the US for first-line treatment of castration-resistant prostate cancer (CRPC): estramustine, mitoxantrone, and docetaxel with prednisone [4], with the docetaxel-prednisone combination being the only treatment shown to improve survival [5, 6].”
BackgroundAbiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407 · cited 1×
“In the postdocetaxel setting, prednisone-based abiraterone [7] and cabazitaxel [8] have been approved for CRPC patients pretreated with docetaxel, while two other agents, alpharadin and MDV3100, are also showing overall survival (OS) benefit in phase 3 studies.”
Backgroundde Bono, J. S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J.-P., Kocak, I., Gravis, G., Bodrogi, I., Mackenzie, M. J., Shen, L., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61389-x · Cited by 3,318
Self-citationScher, H. I., Halabi, S., Tannock, I., Morris, M., Sternberg, C. N., Carducci, M. A., Eisenberger, M. A., Higano, C., Bubley, G. J., Dreicer, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.4487 · Cited by 2,241
de Bono, J. S., Scher, H. I., Montgomery, R. B., Parker, C., Miller, M. C., Tissing, H., Doyle, G. V., Terstappen, L. W. W. M., Pienta, K. J., & Raghavan, D. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0872 · Cited by 2,182
Self-citationBerthold, D. R., Pond, G. R., Soban, F., de Wit, R., Eisenberger, M., & Tannock, I. F. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.4008 · Cited by 1,145
Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer
Danila, D. C., Heller, G., Gignac, G. A., Gonzalez-Espinoza, R., Anand, A., Tanaka, E., Lilja, H., Schwartz, L., Larson, S., Fleisher, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1506 · Cited by 665
Loberg, R. D., Ying, C., Craig, M., Day, L. L., Sargent, E., Neeley, C., Wojno, K., Snyder, L. A., Yan, L., & Pienta, K. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1286 · Cited by 333
Self-citationHaringman, J. J., Gerlag, D. M., Smeets, T. J. M., Baeten, D., van den Bosch, F., Bresnihan, B., Breedveld, F. C., Dinant, H. J., Legay, F., Gram, H., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21975 · Cited by 258
CCL2 is a Potent Regulator of Prostate Cancer Cell Migration and Proliferation
Loberg, R. D., Day, L. L., Harwood, J., Ying, C., St. John, L. N., Giles, R., Neeley, C. K., & Pienta, K. J. (2006) · Neoplasia · doi:10.1593/neo.06280 · Cited by 255
Self-citationLoberg, R. D., Ying, C., Craig, M., Yan, L., Snyder, L. A., & Pienta, K. J. (2007) · Neoplasia · doi:10.1593/neo.07307 · Cited by 242
Self-citationLu, Y., Cai, Z., Galson, D. L., Xiao, G., Liu, Y., George, D. E., Melhem, M. F., Yao, Z., & Zhang, J. (2006) · The Prostate · doi:10.1002/pros.20464 · Cited by 242
Pain Predicts Overall Survival in Men With Metastatic Castration-Refractory Prostate Cancer
Halabi, S., Vogelzang, N. J., Kornblith, A. B., Ou, S.-S., Kantoff, P. W., Dawson, N. A., & Small, E. J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0367 · Cited by 193
A Destructive Cascade Mediated by CCL2 Facilitates Prostate Cancer Growth in Bone
Li, X., Loberg, R. D., Liao, J., Chi, Y., Snyder, L. A., Pienta, K. J., & McCauley, L. K. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2164 · Cited by 153
Self-citationCCR2 expression correlates with prostate cancer progression
Lü, Y., Cai, Z. Y., Xiao, G., Liu, Y., Keller, E. T., Yao, Z., & Zhang, J. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21220 · Cited by 131
The Measurement of Pain from Metastatic Bone Disease: Capturing the Patient's Experience
Cleeland, C. S. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0988 · Cited by 124
Prostate Cancer: A Practical Approach to Current Management of Recurrent Disease
Walczak, J., & Carducci, M. A. (2007) · Mayo Clinic Proceedings · doi:10.4065/82.2.243 · Cited by 71
Mazzucchelli, L., Loetscher, P., Каппелер, А., Uguccioni, M., Baggiolini, M., Laissue, J. A., & Mueller, C. (1996) · PubMed · Cited by 69
Lü, Y., Xiao, G., Galson, D. L., Nishio, Y., Mizokami, A., Keller, E. T., Yao, Z., & Zhang, J. (2007) · International Journal of Cancer · doi:10.1002/ijc.22704 · Cited by 65
Fetterly, G. J., Aras, U., Meholick, P. D., Takimoto, C. H. M., Seetharam, S., McIntosh, T. S., Bono, J. S. D., Sandhu, S. K., Tolcher, A. W., Davis, H. M., et al. (2013) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.140 · Cited by 37
Self-citation
Cited by
Tumour-associated macrophages as treatment targets in oncology
Mantovani, A., Marchesi, F., Malesci, A., Laghi, L., & Allavena, P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.217 · Cited by 4,033
Targeting macrophages: therapeutic approaches in cancer
Cassetta, L., & Pollard, J. W. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.169 · Cited by 2,048
Macrophages as tools and targets in cancer therapy
Mantovani, A., Allavena, P., Marchesi, F., & Garlanda, C. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00520-5 · Cited by 1,807
Tumor microenvironment and therapeutic response
Wu, T., & Dai, Y. (2017) · Cancer Letters · doi:10.1016/j.canlet.2016.01.043 · Cited by 1,802
Immune cell promotion of metastasis
Kitamura, T., Qian, B.-Z., & Pollard, J. W. (2015) · Nature Reviews Immunology · doi:10.1038/nri3789 · Cited by 1,158
Metadata
- Authors
- Pienta, K. J., Machiels, J.-P., Schrijvers, D., Alekseev, B., Shkolnik, M., Crabb, S. J., Li, S., Seetharam, S., Puchalski, T. A., Takimoto, C., Elsayed, Y., Dawkins, F., & de Bono, J. S.
- Venue
- Investigational New Drugs
- Published
- 2012-08-21
- Volume
- 31
- Issue
- 3
- Pages
- 760-768
- ISSN
- 0167-6997 (ISSN-L)
- 1573-0646
- OpenAlex
- W2071959986
- Cited by
- 412
- References
- 22
- FWCI
- 9.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.